on The Vanguard Group, Inc. (isin : US12572Q1058)
Vanguard Group Discloses Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has disclosed its interest in Avadel Pharmaceuticals plc, as required by the Irish Takeover Panel under Rule 8.3. This disclosure, dated 26 December 2025, reveals that Vanguard holds 5,864,733 US$0.01 ordinary shares, representing a 6.02% stake in the pharmaceutical company.
The filing follows dealings conducted on 24 December 2025, including a purchase of 752 shares at a price of 21.58 USD per share. No derivative or options agreements are reported in this disclosure.
No indemnity, option arrangements, or agreements related to voting rights or future securities transactions were noted. Additionally, Vanguard has not attached any Supplemental Form 8, confirming no further complex financial instruments are involved.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news